GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CONV 01-alpha overview
CONV 01-alpha (225Ac−J591) is under development for the treatment of metastatic castration−resistant prostate cancer (CRPC). The drug candidate is a radio labeled (actinium-225) humanized monoclonal antibody administered as an intravenous route. It targets prostate specific membrane antigen (PSMA).
Convergent Therapeutics overview
Convergent Therapeutics is a pharmaceutical company, developing next-generation radiopharmaceutical therapy for prostate cancer and other applications. It is headquartered in New York City, New York, the US.
For a complete picture of CONV 01-alpha’s drug-specific PTSR and LoA scores, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.